EGLN3 Inhibition of NF-κB Is Mediated by Prolyl Hydroxylase-Independent Inhibition of IκB Kinase γ Ubiquitination

Molecular and Cellular Biology

Volumn 33, Issue 15, 2013, Pages 3050-3061

  Fu, Jian ^a   Taubman, Mark B ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIAP1 PROTEIN; EGLN1 PROTEIN; EGLN2 PROTEIN; EGLN3 PROTEIN; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICROORGANISM PROTEIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; UBCH5 PROTEIN; UBIQUITIN CONJUGATING ENZYME 13; UBIQUITIN CONJUGATING ENZYME E2; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DEUBIQUITINATION; EMBRYO; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; CELL LINE; DIOXYGENASES; HUMANS; I-KAPPA B KINASE; INHIBITOR OF APOPTOSIS PROTEINS; NF-KAPPA B; PROCOLLAGEN-PROLINE DIOXYGENASE; PROTEIN INTERACTION MAPS; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84880658083     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00273-13     Document Type: Article

References (68)

1. Kaelin WG, Jr, Ratcliffe PJ. 2008. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30:393-402.
2. Wax SD, Rosenfield CL, Taubman MB. 1994. Identification of a novel growth factor-responsive gene in vascular smooth muscle cells. J. Biol. Chem. 269:13041-13047.
3. Madden SL, Galella EA, Riley D, Bertelsen AH, Beaudry GA. 1996. Induction of cell growth regulatory genes by p53. Cancer Res. 56:5384-5390.
4. Lipscomb EA, Sarmiere PD, Crowder RJ, Freeman RS. 1999. Expression of the SM-20 gene promotes death in nerve growth factor-dependent sympathetic neurons. J. Neurochem. 73:429-432.
5. Fu J, Menzies K, Freeman RS, Taubman MB. 2007. EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability. J. Biol. Chem. 282:12410-12418.
6. Gerber SA, Yatsula B, Maier CL, Sadler TJ, Whittaker LW, Pober JS. 2009. Interferon-γ induces prolyl hydroxylase PHD3 through a STAT1-dependent mechanism in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 29:1363-1369.
7. Su Y, Loos M, Giese N, Hines OJ, Diebold I, Gorlach A, Metzen E, Pastorekova S, Friess H, Buchler P. 2010. PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br. J. Cancer 103:1571-1579.
8. Henze AT, Riedel J, Diem T, Wenner J, Flamme I, Pouyseggur J, Plate KH, Acker T. 2010. Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors. Cancer Res. 70:357-366.
9. Fu J, Taubman MB. 2010. Prolyl hydroxylase EGLN3 regulates skeletal myoblast differentiation through an NF-κB-dependent pathway. J. Biol. Chem. 285:8927-8935.
10. Xue J, Li X, Jiao S, Wei Y, Wu G, Fang J. 2010. Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKβ independent of hydroxylase activity. Gastroenterology 138:606-615.
11. Takeda Y, Costa S, Delamarre E, Roncal C, Leite de Oliveira R, Squadrito ML, Finisguerra V, Deschoemaeker S, Bruyere F, Wenes M, Hamm A, Serneels J, Magat J, Bhattacharyya T, Anisimov A, Jordan BF, Alitalo K, Maxwell P, Gallez B, Zhuang ZW, Saito Y, Simons M, De Palma M, Mazzone M. 2011. Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature 479:122-126.
12. Scheidereit C. 2006. IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene 25:6685-6705.
13. Rudolph D, Yeh WC, Wakeham A, Rudolph B, Nallainathan D, Potter J, Elia AJ, Mak TW. 2000. Severe liver degeneration and lack of NF-κB activation in NEMO/IKKγ-deficient mice. Genes Dev. 14:854-862.
14. Schmidt-Supprian M, Bloch W, Courtois G, Addicks K, Israel A, Rajewsky K, Pasparakis M. 2000. NEMO/IKKγ-deficient mice model incontinentia pigmenti. Mol. Cell 5:981-992.
15. Makris C, Godfrey VL, Krahn-Senftleben G, Takahashi T, Roberts JL, Schwarz T, Feng L, Johnson RS, Karin M. 2000. Female mice heterozygous for IKKγ/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol. Cell 5:969-979.
16. Tang ED, Wang CY, Xiong Y, Guan KL. 2003. A role for NF-κB essential modifier/IκB kinase-γ (NEMO/IKKγ) ubiquitination in the activation of the IκB kinase complex by tumor necrosis factor-α. J. Biol. Chem. 278:37297-37305.
17. Zhou H, Wertz I, O'Rourke K, Ultsch M, Seshagiri S, Eby M, Xiao W, Dixit VM. 2004. Bcl10 activates the NF-κB pathway through ubiquitination of NEMO. Nature 427:167-171.
18. Abbott DW, Wilkins A, Asara JM, Cantley LC. 2004. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr. Biol. 14:2217-2227.
19. Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. 2004. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol. Cell 14:289-301.
20. Sebban-Benin H, Pescatore A, Fusco F, Pascuale V, Gautheron J, Yamaoka S, Moncla A, Ursini MV, Courtois G. 2007. Identification of TRAF6-dependent NEMO polyubiquitination sites through analysis of a new NEMO mutation causing incontinentia pigmenti. Hum. Mol. Genet. 16:2805-2815.
21. Tokunaga F, Sakata S, Saeki Y, Satomi Y, Kirisako T, Kamei K, Nakagawa T, Kato M, Murata S, Yamaoka S, Yamamoto M, Akira S, Takao T, Tanaka K, Iwai K. 2009. Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nat. Cell Biol. 11:123-132.
22. Rahighi S, Ikeda F, Kawasaki M, Akutsu M, Suzuki N, Kato R, Kensche T, Uejima T, Bloor S, Komander D, Randow F, Wakatsuki S, Dikic I. 2009. Specific recognition of linear ubiquitin chains by NEMO is important for NF-κB activation. Cell 136:1098-1109.
23. Grabbe C, Husnjak K, Dikic I. 2011. The spatial and temporal organization of ubiquitin networks. Nat. Rev. Mol. Cell Biol. 12:295-307.
24. Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL, Webb AI, Rickard JA, Anderton H, Wong WW, Nachbur U, Gangoda L, Warnken U, Purcell AW, Silke J, Walczak H. 2011. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471:591-596.
25. Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S, Tanaka K, Nakano H, Iwai K. 2011. SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex. Nature 471:633-636.
26. Ikeda F, Deribe YL, Skanland SS, Stieglitz B, Grabbe C, Franz-Wachtel M, van Wijk SJ, Goswami P, Nagy V, Terzic J, Tokunaga F, Androulidaki A, Nakagawa T, Pasparakis M, Iwai K, Sundberg JP, Schaefer L, Rittinger K, Macek B, Dikic I. 2011. SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis. Nature 471:637-641.
27. Wang L, Du F, Wang X. 2008. TNF-α induces two distinct caspase-8 activation pathways. Cell 133:693-703.
28. Fu J, Jin Y, Arend LJ. 2003. Smac3, a novel Smac/DIABLO splicing variant, attenuates the stability and apoptosis-inhibiting activity of Xlinked inhibitor of apoptosis protein. J. Biol. Chem. 278:52660-52672.
29. Nakayama K, Gazdoiu S, Abraham R, Pan ZQ, Ronai Z. 2007. Hypoxiainduced assembly of prolyl hydroxylase PHD3 into complexes: implications for its activity and susceptibility for degradation by the E3 ligase Siah2. Biochem. J. 401:217-226.
30. Arimoto K, Funami K, Saeki Y, Tanaka K, Okawa K, Takeuchi O, Akira S, Murakami Y, Shimotohno K. 2010. Polyubiquitin conjugation to NEMO by triparite motif protein 23 (TRIM23) is critical in antiviral defense. Proc. Natl. Acad. Sci. U. S. A. 107:15856-15861.
31. Sato M, Sakota M, Nakayama K. 2010. Human PRP19 interacts with prolyl-hydroxylase PHD3 and inhibits cell death in hypoxia. Exp. Cell Res. 316:2871-2882.
32. Wu ZH, Wong ET, Shi Y, Niu J, Chen Z, Miyamoto S, Tergaonkar V. 2010. ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol. Cell 40:75-86.
33. Laplantine E, Fontan E, Chiaravalli J, Lopez T, Lakisic G, Veron M, Agou F, Israel A. 2009. NEMO specifically recognizes K63-linked polyubiquitin chains through a new bipartite ubiquitin-binding domain. EMBO J. 28:2885-2895.
34. Hu S, Yang X. 2003. Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. J. Biol. Chem. 278: 10055-10060.
35. Csomos RA, Wright CW, Galban S, Oetjen KA, Duckett CS. 2009. Two distinct signalling cascades target the NF-κB regulatory factor c-IAP1 for degradation. Biochem. J. 420:83-91.
36. Mankouri J, Fragkoudis R, Richards KH, Wetherill LF, Harris M, Kohl A, Elliott RM, Macdonald A. 2010. Optineurin negatively regulates the induction of IFNβ in response to RNA virus infection. PLoS Pathog. 6:e1000778. doi:10.1371/journal.ppat.1000778.
37. Nakada S, Tai I, Panier S, Al-Hakim A, Iemura S, Juang YC, O'Donnell L, Kumakubo A, Munro M, Sicheri F, Gingras AC, Natsume T, Suda T, Durocher D. 2010. Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1. Nature 466:941-946.
38. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. 2003. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424:797-801.
39. Storz P, Doppler H, Ferran C, Grey ST, Toker A. 2005. Functional dichotomy of A20 in apoptotic and necrotic cell death. Biochem. J. 387:47-55.
40. Shembade N, Harhaj NS, Parvatiyar K, Copeland NG, Jenkins NA, Matesic LE, Harhaj EW. 2008. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat. Immunol. 9:254-262.
41. Borodovsky A, Ovaa H, Kolli N, Gan-Erdene T, Wilkinson KD, Ploegh HL, Kessler BM. 2002. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 9:1149-1159.
42. Cotto-Rios XM, Jones MJ, Busino L, Pagano M, Huang TT. 2011. APC/CCdh1-dependent proteolysis of USP1 regulates the response to UV-mediated DNA damage. J. Cell Biol. 194:177-186.
43. Niu J, Shi Y, Iwai K, Wu ZH. 2011. LUBAC regulates NF-κB activation upon genotoxic stress by promoting linear ubiquitination of NEMO. EMBO J. 30:3741-3753.
44. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. 2003. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 424:801-805.
45. Hutti JE, Turk BE, Asara JM, Ma A, Cantley LC, Abbott DW. 2007. IκB kinase β phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-κB pathway. Mol. Cell. Biol. 27:7451-7461.
46. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes K, Dixit VM, Vucic D. 2007. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα- dependent apoptosis. Cell 131:669-681.
47. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M, Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J. 2007. IAP antagonists target cIAP1 to induce TNFα- dependent apoptosis. Cell 131:682-693.
48. Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E, Feltham R, Vince J, Warnken U, Wenger T, Koschny R, Komander D, Silke J, Walczak H. 2009. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol. Cell 36:831-844.
49. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG. 2000. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403:103-108.
50. Hayden MS, Ghosh S. 2008. Shared principles in NF-κB signaling. Cell 132:344-362.
51. Shibata Y, Oyama M, Kozuka-Hata H, Han X, Tanaka Y, Gohda J, Inoue J. 2012. p47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO. Nat. Commun. 3:1061. doi:10.1038/ncomms2068.
52. Bist P, Leow SC, Phua QH, Shu S, Zhuang Q, Loh WT, Nguyen TH, Zhou JB, Hooi SC, Lim LH. 2011. Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-κB: implication in breast cancer metastasis. Oncogene 30:3174-3185.
53. Huang J, Teng L, Li L, Liu T, Chen D, Xu LG, Zhai Z, Shu HB. 2004. ZNF216 is an A20-like and IκB kinase γ-interacting inhibitor of NFκB activation. J. Biol. Chem. 279:16847-16853.
54. Bouchier-Hayes L, Conroy H, Egan H, Adrain C, Creagh EM, MacFarlane M, Martin SJ. 2001. CARDINAL, a novel caspase recruitment domain protein, is an inhibitor of multiple NF-κB activation pathways. J. Biol. Chem. 276:44069-44077.
55. Bruick RK, McKnight SL. 2001. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294:1337-1340.
56. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG, Jr. 2001. HIFαtargeted for VHL-mediated destruction by proline hydroxylation: implications forO2 sensing. Science 292:464-468.
57. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. 2001. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex byO2-regulated prolyl hydroxylation. Science 292:468-472.
58. 2-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL. Sci. Signal. 2:ra33. doi:10.1126/scisignal.2000444.
59. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A, Semenza GL. 2011. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145:732-744.
60. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, Taylor CT. 2006. Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity. Proc. Natl. Acad. Sci. U. S. A. 103:18154-18159.
61. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, Giaccia AJ. 2009. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 15:527-538.
62. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. 2006. Activation of IKK by TNFα requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 22:245-257.
63. Ramakrishnan P, Baltimore D. 2011. Sam68 is required for both NF-κB activation and apoptosis signaling by the TNF receptor. Mol. Cell 43:167-179.
64. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, Barker PA. 2008. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30:689-700.
65. Hadian K, Griesbach RA, Dornauer S, Wanger TM, Nagel D, Metlitzky M, Beisker W, Schmidt-Supprian M, Krappmann D. 2011. NF-κB essential modulator (NEMO) interaction with linear and lys-63 ubiquitin chains contributes to NF-κB activation. J. Biol. Chem. 286:26107-26117.
66. Kulathu Y, Komander D. 2012. Atypical ubiquitylation-the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat. Rev. Mol. Cell Biol. 13:508-523.
67. Kanayama A, Seth RB, Sun L, Ea CK, Hong M, Shaito A, Chiu YH, Deng L, Chen ZJ. 2004. TAB2 and TAB3 activate the NF-κB pathway through binding to polyubiquitin chains. Mol. Cell 15:535-548.
68. Komander D, Reyes-Turcu F, Licchesi JD, Odenwaelder P, Wilkinson KD, Barford D. 2009. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep. 10:466-473.